[go: up one dir, main page]

WO2008063113A8 - Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf - Google Patents

Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf Download PDF

Info

Publication number
WO2008063113A8
WO2008063113A8 PCT/SE2007/001017 SE2007001017W WO2008063113A8 WO 2008063113 A8 WO2008063113 A8 WO 2008063113A8 SE 2007001017 W SE2007001017 W SE 2007001017W WO 2008063113 A8 WO2008063113 A8 WO 2008063113A8
Authority
WO
WIPO (PCT)
Prior art keywords
cell
peptide
amino acids
penetrating peptides
p19arf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2007/001017
Other languages
French (fr)
Other versions
WO2008063113A1 (en
Inventor
Uelo Langel
Henrik Johansson
Samir El-Andaloussi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CEPEP III AB
Original Assignee
CEPEP III AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CEPEP III AB filed Critical CEPEP III AB
Publication of WO2008063113A1 publication Critical patent/WO2008063113A1/en
Anticipated expiration legal-status Critical
Publication of WO2008063113A8 publication Critical patent/WO2008063113A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A cell-penetrating peptide or a construct comprising such a peptide of 15 to 25 amino acids comprising at least amino acids 1 - 14 of a mature mammalian tumor suppressor protein ARF or a scrambled or partially inverted sequence thereof, such as the human p14ARF protein SEQ ID NO:2, and the partially inverted sequence thereof SEQ ID NO: 1 optionally linked to one or more of a cargo, such as an anti-cancer drug, a detection marker, a cell-homing peptide, such as a tumor-homing peptide, a receptor ligand, a linker, and a peptide spacer comprising a selective protease cleavage site coupled to an inactivating peptide, is disclosed. The cell-penetrating peptides of the invention derived from ARF can either be biologically inert or have biological activity in themselves. Further, a method of delivering a cargo into a target cell in vivo or in vitro, is described.
PCT/SE2007/001017 2006-11-20 2007-11-19 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf Ceased WO2008063113A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85993006P 2006-11-20 2006-11-20
SE0602459-0 2006-11-20
SE0602459 2006-11-20
US60/859,930 2006-11-20

Publications (2)

Publication Number Publication Date
WO2008063113A1 WO2008063113A1 (en) 2008-05-29
WO2008063113A8 true WO2008063113A8 (en) 2009-07-23

Family

ID=39429957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/001017 Ceased WO2008063113A1 (en) 2006-11-20 2007-11-19 Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf

Country Status (1)

Country Link
WO (1) WO2008063113A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016050934A1 (en) * 2014-10-02 2016-04-07 Aliophtha Ag Endosomal disentanglement of artificial transcription factors
US9822180B2 (en) 2012-02-28 2017-11-21 The University Of Birmingham Immunotherapeutic molecules and uses

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI121959B (en) 2008-05-09 2011-06-30 Pirjo Laakkonen Peptide seeking for brain tumors
DK3252068T3 (en) 2009-10-12 2025-08-25 Larry J Smith METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING OLIGONUCLEOTIDE-BASED DRUGS ADMINISTERED IN VIVO OR IN VITRO
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CN103096911B (en) 2010-04-27 2018-05-29 Atyr 医药公司 Treatment relevant with the protein fragments of Isoleucyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
JP6008838B2 (en) 2010-04-29 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase
AU2011248230B2 (en) 2010-05-03 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
EP2566495B1 (en) 2010-05-03 2017-03-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
AU2011248355B2 (en) 2010-05-03 2017-01-19 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases
JP6008844B2 (en) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of the p38 MULTI-tRNA synthetase complex
CN103200953B (en) 2010-05-14 2017-02-15 Atyr 医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
EP2575857B1 (en) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
CN103118695B (en) 2010-07-12 2016-08-03 Atyr医药公司 Discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
CN103108650A (en) 2010-08-25 2013-05-15 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
DK2686020T3 (en) 2011-03-17 2017-05-01 Univ Birmingham REDIRECTED IMMUNTERY
EP2782926B1 (en) 2011-11-24 2018-07-04 Positec Power Tools (Suzhou) Co., Ltd Peptide sequence design and use thereof for peptide-mediated sirna delivery
EP2904008A1 (en) 2012-10-05 2015-08-12 Eastern Virginia Medical School A family of synthetic polynucleotide-binding peptides and uses thereof
TW201514202A (en) 2013-04-03 2015-04-16 Aliophtha Ag Artificial transcription factors engineered to overcome endosomal entrapment
AR095985A1 (en) * 2013-04-03 2015-11-25 Aliophtha Ag ARTIFICIAL TRANSCRIPTION FACTORS AND THEIR USE TO TREAT THE INAPPROPRIATE HEALING OF EYE WOUNDS
JP2018508481A (en) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム Targeted partial peptide epitope complex having multiple T cell epitopes
HUE054131T2 (en) 2015-11-19 2021-08-30 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
KR102167755B1 (en) 2018-05-23 2020-10-19 주식회사 큐어바이오 Fragmented GRS polypeptide, mutants thereof and use thereof
CN109553659B (en) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 Cell penetrating peptide and transdermal interferon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US7339042B2 (en) * 2003-06-09 2008-03-04 University Of Florida Research Foundation, Inc. Gene delivery to tumors
KR20060054196A (en) * 2003-06-10 2006-05-22 주식회사 툴젠 Deliverable DNA-binding Protein
WO2005117928A1 (en) * 2004-05-30 2005-12-15 Cemines, Inc. Compositions and methods for the treatment of skin cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9822180B2 (en) 2012-02-28 2017-11-21 The University Of Birmingham Immunotherapeutic molecules and uses
US10106621B2 (en) 2012-02-28 2018-10-23 The University Of Birmingham Immunotherapeutic molecules and uses
WO2016050934A1 (en) * 2014-10-02 2016-04-07 Aliophtha Ag Endosomal disentanglement of artificial transcription factors

Also Published As

Publication number Publication date
WO2008063113A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008063113A8 (en) Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
CN101842109B (en) Peptides derivatized with A-B-C-D- and their therapeutical use
EP1966240B3 (en) Lactoferrin peptides useful as cell-penetrating peptides
EP4556567A2 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
ES2343061T3 (en) DNA METHODS AND CONSTRUCTS FOR PRODUCTION OF HIGH PERFORMANCE POLYPEPTIDES.
EP3059244B1 (en) C-met protein agonist
US20020169125A1 (en) Recombinant production of polyanionic polymers and uses thereof
EP2570430A3 (en) Peptide vaccines with Seq ID No: 78, 41, 44, 46 or 48 for cancers expressing tumor-associated antigens
CA2766039A1 (en) Arginase formulations and methods
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
CN100579986C (en) Method for producing insulinotropic hormone secretion peptide GLP-1(7-36) and GLP-1 analogue
SK283485B6 (en) Parathyroid hormone derivatives, processes for their preparation and pharmaceutical compositions containing them
US20130123199A1 (en) Protein complex for intracellular delivery and uses thereof
US20230203098A1 (en) Human transferrin receptor binding peptide
JP2005511614A (en) Novel epidermal growth factor protein and gene and method of use thereof
ES2627066T3 (en) Recombinant elastase proteins and their manufacturing and use procedures
MX2007004116A (en) Vasoactive intestinal polypeptide pharmaceuticals.
EP1924601B1 (en) Expression of proteins in e.coli
KR101898502B1 (en) Insulin-like growth factor 1 receptor binding peptides
US20100041153A1 (en) Expression of Proteins in E. Coli
JP2016524594A (en) Gene transfer facilitating factor Protransduzin B
WO2012073048A3 (en) Variants of ignar
KR102274876B1 (en) Novel cell penetrating peptides and use thereof
KR20140046994A (en) Cell penetrating peptide comprising np2 polypeptide or dnp2 polypeptide derived from human nlbp and cargo delivery system using the same
EP4056233A1 (en) Ferritin enclosing peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07835215

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07835215

Country of ref document: EP

Kind code of ref document: A1